Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Augmentative and Alternative Communication (Baltimore, Md. : 1985)|March 25, 2022
Current preparation status in AAC: perspectives of special education teachers in the United StatesM Alexandra Da Fonte, Miriam C Boesch, Emily R DeLuca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 7, 2019
The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and CanadaM de Bruin-Weller, A Gadkari, S Auziere, et al.
The British Journal of Dermatology|June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialK Papp, D Thaçi, K Reich, et al.
Ostomy/Wound Management|March 23, 1999
The role of Apligraf in the treatment of venous leg ulcersK Dolynchuk, P Hull, L Guenther, et al.
The British Journal of Dermatology|April 25, 2019
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III studyD Thaçi, K Papp, D Marcoux, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
The Journal of Prevention of Alzheimer'S Disease|September 29, 2021
Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task ForceJ Kaye, P Aisen, R Amariglio, et al.
Nature|April 13, 2018
Reversible Mn<sup>2+</sup>/Mn<sup>4+</sup> double redox in lithium-excess cathode materialsJinhyuk Lee, Daniil A Kitchaev, Deok-Hwang Kwon, et al.
Vaccine|January 12, 2011
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illnessJ M Langley, F Aoki, B J Ward, et al.
The British Journal of Dermatology|April 22, 2020
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)A S Paller, M M B Seyger, G Alejandro Magariños, et al.
Pageof 12